7.17
+0.22(+3.17%)
Currency In USD
| Previous Close | 6.95 |
| Open | 7.1 |
| Day High | 7.5 |
| Day Low | 6.82 |
| 52-Week High | 26.6 |
| 52-Week Low | 5.12 |
| Volume | 50,546 |
| Average Volume | 48,903 |
| Market Cap | 22.79M |
| PE | 0.18 |
| EPS | 39.4 |
| Moving Average 50 Days | 7.08 |
| Moving Average 200 Days | 9.62 |
| Change | 0.22 |
If you invested $1000 in Passage Bio, Inc. (PASG) since IPO date, it would be worth $16.15 as of August 18, 2025 at a share price of $7.17. Whereas If you bought $1000 worth of Passage Bio, Inc. (PASG) shares 3 years ago, it would be worth $168.31 as of August 18, 2025 at a share price of $7.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Passage Bio Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Jul 10, 2025 11:00 AM GMT
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announce
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire Inc.
Jun 23, 2025 11:00 AM GMT
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days
Passage Bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in